Related Experiment Videos
In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin
S E Gasanov1, E D Rael, N E Gasanov
1Department of Biological Sciences, University of Texas at El Paso 79968, USA.
Cancer Immunology, Immunotherapy : CII
|August 1, 1995
Summary
This study developed a novel immunotoxin by conjugating Pyrularia thionin to an anti-CD5 antibody. This Pyrularia-thionin-anti-CD5 conjugate effectively targets and eliminates CD5+ lymphocytes, showing promise for treating graft-versus-host disease and CD5+ leukemias.
Area of Science:
- Immunology
- Biochemistry
- Cell Biology
Background:
- Pyrularia thionin is a membrane-active peptide with potential therapeutic applications.
- Targeting CD5+ cells is a strategy for treating certain immune disorders and cancers.
Purpose of the Study:
- To create and evaluate a novel immunotoxin by conjugating Pyrularia thionin to an anti-CD5 monoclonal antibody.
- To assess the efficacy and mechanism of action of the resulting immunotoxin against CD5+ lymphocytes.
Main Methods:
- Covalent conjugation of Pyrularia thionin to an anti-CD5 monoclonal antibody.
- In vitro cytotoxicity assays using CD5+ lymphocytes.
- T cell proliferation assays (mitogen-stimulated and mixed lymphocyte reaction).
- Membrane perturbation studies using electron paramagnetic resonance and differential scanning calorimetry.
Main Results:
- The Pyrularia-thionin-anti-CD5 immunotoxin retained the membrane-active properties of thionin.
- The immunotoxin demonstrated potent in vitro killing of CD5+ lymphocytes.
- It effectively inhibited T cell proliferation in response to mitogens and in mixed lymphocyte reactions.
- Membrane perturbation studies confirmed the immunotoxin's ability to alter lipid phases similarly to unconjugated thionin.
Conclusions:
- The Pyrularia-thionin-anti-CD5 conjugate is a promising therapeutic agent.
- Potential applications include the treatment of graft-versus-host disease.
- It may also be beneficial for treating CD5+ leukemias and lymphomas.